RxDoctor Payments DataLook up a doctor →

Rohit Amin, MD

Interventional Cardiology · Pensacola, FLNPI 1316139041

Payments from drug & device makers

$2,047,443in general payments, 2019–2025

Across 1,462 payments — averaging $1400.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$477K
  • Amgen$473K
  • Endotronix, Inc.$365K
  • Inari Medical, Inc.$225K
  • AstraZeneca$171K
  • American Regent$125K
  • plus $213K from 53 others

What the payments were for

  • Consulting fees$35,7406%
  • Speaking & faculty fees$382,17168%
  • Travel & lodging$89,79516%
  • Food & beverage$52,2819%
  • Education$1780%
  • Entertainment$1440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis20$476,653
Amgen320$472,503
Endotronix, Inc.11$364,975
Inari Medical, Inc.188$224,948
AstraZeneca238$171,160
American Regent20$124,560
Cvrx, Inc.19$38,737
Procyrion, Inc.8$31,249
Abbott160$23,341
Centerline Biomedical Inc.5$21,424
Alnylam Pharmaceuticals Inc.3$17,250
United Therapeutics Corporation22$14,654
Recor Medical Inc16$12,399
Stryker10$7,085
Bayer5$7,067
Abiomed71$6,260
Penumbra, Inc.30$5,595
Ancora Heart, Inc.26$5,406
Shockwave Medical, Inc14$4,816
Actelion Pharmaceuticals, Ltd4$3,850
Medtronic(2 entities)34$1,895
Boehringer Ingelheim International GmbH1$1,489
Boston Scientific32$1,396
Johnson & Johnson45$1,121
Actelion Pharmaceuticals US, Inc.34$914
Philips North America LLC10$829
Boehringer Ingelheim16$570
Imperative Care, Inc4$473
Pfizer19$459
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)7$416
Opsens Inc.6$390
E.r. Squibb & Sons, L.L.C.7$310
Edwards Lifesciences2$294
Merck6$273
Angiodynamics, Inc.3$250
Sanofi-aventis U.S. LLC3$241
Livanova USA, Inc.2$208
Cook Medical LLC2$176
W. L. Gore & Associates, Inc.3$169
Terumo Medical Corporation3$168
Scpharmaceuticals Inc.6$158
Bard Peripheral Vascular, Inc.1$152
Teleflex LLC1$131
Heartflow, Inc.1$117
Janssen Scientific Affairs, LLC1$114
Contego Medical, Inc1$95
Chiesi USA, Inc.1$85
Cardiva Medical, Inc.1$82
Cardiovascular Systems Inc.2$82
Sensible Medical Innovations Inc1$80
Biotronik Inc.1$78
BD3$69
Esperion Therapeutics, Inc.2$51
Gilead4$49
Novo Nordisk2$48
GE HealthCare2$39
Irhythm Technologies, Inc.1$16
Amarin Pharma, Inc.1$13
Portola Pharmaceuticals, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,047,443 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$460,135
Medicare patients
1,751
Services billed
4,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag18$457,647
OpsumitMacitentan24$331,451
EliquisApixaban286$269,369
BrilintaTicagrelor235$204,622
AdempasRiociguat11$153,350
XareltoRivaroxaban163$148,498
EntrestoSacubitril/Valsartan105$129,111
FarxigaDapagliflozin Propanediol112$94,877
Repatha SureclickEvolocumab68$75,994
JardianceEmpagliflozin17$30,468
Repatha PushtronexEvolocumab29$28,856
ClopidogrelClopidogrel Bisulfate602$6,727
Atorvastatin Calcium446$6,389
Carvedilol543$4,494
Ranolazine ErRanolazine53$4,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$914$789,09842 claims
AstraZenecaBrilinta, Farxiga$171,160$299,499347 claims
PfizerEliquis$459$269,369286 claims
BayerAdempas$7,067$153,35011 claims
Johnson & JohnsonXarelto$1,121$148,498163 claims
NovartisEntresto$476,653$129,111105 claims
Boehringer IngelheimJardiance$570$30,46817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →